个人简介

Program Chair, World Molecular Imaging Congress, 2014 UA Arizona Engineering Faculty Fellow, 2010-2014 Sydney E. Salmon Distinguished Junior Investigator Award, Arizona Cancer Center, 2010 Graduate Teaching Award, CWRU, Cleveland, OH, 2007

研究领域

Biochemistry/Physical/Bioanalytical/Chemical Biology/Spectroscopy/molecular Structure

Picturing the Future of Cancer Health Care The Contrast Agent Molecular Engineering Laboratory (CAMEL) develops new biomedical imaging methods that provide molecular-level diagnoses of cancer. We use our chemistry expertise to develop chemical agents that change the contrast of biomedical images. These contrast agents are designed to respond to molecular biomarkers of biological processes and pathologies. This molecular information is used to predict response to therapy before the therapy is applied, monitor the delivery of therapy to targeted tissues, and evaluate the early-stage effects of the therapy. These diagnostic methods that affect the choice of therapy are designed to provide personalized medicine for each individual patient. CAMEL has specialized in developing a new type of MRI contrast agent that can detect molecular biomarkers through Chemical Exchange Saturation Transfer (CEST). CAMEL has developed methods to synthesize CEST MRI contrast agents, has pioneered the development of CEST MRI methods for pre-clinical studies, and has started clinical trials to translate CEST "from bench to bedside". CAMEL also develops contrast agents for optical imaging, particularly focusing on applications of optical imaging that use multiple agents to improve the specificity of molecular imaging.

近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Cárdenas-Rodríguez J, Howison CM, Pagel, MD. A linear algorithm of the reference region model for DCE-MRI is robust and relaxes requirements for temporal resolution. Magn Reson Imaging 2013, 31(4):497-507. PMID 23228309, DOI: 10.1016/j.mri.2012.10.008. Yoo B, Pagel MD. Lanthanide-mediated dephosphorylation used for peptide cleavage during solid phase peptide synthesis. Molecules 2013, 18:3894-3905. PMID 23549296, DOI: 10.3390/molecules18043894. Hingorani DV, Randtke EA, Pagel MD. A CatalyCEST MRI contrast agent that detects the enzyme- catalyzed creation of a covalent bond. J Am Chem Soc 2013, 135(17):6396-6398. PMID 23601132, DOI: 10.1021/ja400254e. Cárdenas-Rodríguez J, Howison CM, Matsunaga TO, Pagel MD. A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agents. Magn Reson Imaging 2013, 31:900-910. PMID 23583323, DOI: 10.1016/j.mri.2012.12.002. Yoo B, Sheth VR, Howison CM, Douglas MJK, Pineda CT, Maine EA, Baker AF, Pagel MD. Detection of in vivo enzyme activity with CatalyCEST MRI. Mag Reson Med 2013, 71(3):1221-1230. PMID 23640714, DOI: 10.1002/mrm.24763. Hingorani DV, Gonzalez SI, Li JF, Pagel MD. Sensing lanthanide metal content in biological tissues with magnetic resonance spectroscopy. Sensors 2013, 13:13732-13743. PMID 24152931, DOI: 10.3390/s131013732. Leung HM, Schafer R, Pagel MD, Robey IF, Gmitro AF. Multimodality pH imaging in a mouse dorsal skin fold window chamber model. Proc. SPIE 8574, Multimodal Biomedical Imaging VIII, 2013, 85740L. Chen LQ, Howison CM, Jeffery JJ, Robey IF, Kuo PH, Pagel MD. Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI. Magn Reson Med, 2013, epub ahead of print. PMID: 24281951, DOI: 10.1002/mrm.25053. Randtke EA, Chen LQ, Correales LR, Pagel MD. The Hanes-Woolf Linear QUESP method improves the measurements of fast chemical exchange rates with CEST MRI. Magn Reson Med 2014, 71(4):1603-1612. PMID 23780911, DOI: 10.1002/mrm.24792. Randtke EA, Chen LQ, Pagel MD. The reciprocal linear QUEST analysis method facilitates the measurements of chemical exchange rates with CEST MRI. Contrast Media Molec Imaging, 2014, 9:252-258. PMID: 24700753, DOI: 10.1002/cmmi.1566. Jeffery JJ, Lux K, Vogel JS, Herrera WD, Greco S, Woo HH, Abu Shahin N, Pagel MD, Chambers SK. Autocrine inhibition of the c-fms proto-oncogene reduces breast cancer bone metastasis assessed with in vivo dual-modality imaging. Exp Bio Med 2014; 239:404-413. PMID: 24599884, DOI: 10.1177/1535370214522588. Lee J, Cárdenas-Rodríguez J, Pagel MD, Platt S, Marc Kent M, Zhao Q. Comparison of analytical and numerical analysis of the reference region model for DCE-MRI. Magn Reson Imaging 2014, 32(7):845-853. PMID: 24925838, DOI: 10.1016/j.mri.2014.04.007. Zhang X, Pagel MD, Baker AM, Gillies RJ. Reproducibility of magnetic resonance perfusion imaging. PLOS One, 2014, 9(2):e89797. PMID: 24587040, DOI: 10.1371/journal.pone.0089797. Hingorani DV, Yoo B, Bernstein AS, Pagel MD. Detecting enzyme activities with exogenous MRI contrast agents. Chem Euro J, 2014, Epub ahead of print. PMID: 24990812, DOI: 10.1002/chem.201402474. Chen LQ, Howison CM, Spier C, Stopeck AT, Malm SW, Pagel MD, Baker AF. Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models. Leukemia Lymphoma 2014, accepted for publication. Lucero-Acuña A, Jeffery JJ, Abril ER, Nagle R, Guzman R, Pagel MD, Meuillet EJ. Nanoparticle Delivery of a AKT/PDK1 Inhibitor Improves the Therapeutic Effect Against Pancreatic Cancer. Int J Nanotech. accepted for publication. Jones KM, Randtke EA, Howison CM, Cárdenas-Rodríguez J, Sime PJ, Kottmann RM, Pagel MD. Measuring Extracellular pH in a Lung Fibrosis Model with acidoCEST MRI. Molec Imaging Biol 2014, accepted for publication. Hingorani DV, Bernstein AS, Pagel MD. A review of responsive MRI contrast agents: 2005-2014. Contrast Media Molec Imaging 2014, accepted for publication.